Chen Runzhe, Wang Fei, Zhang Xiaoping, Gao Chong, Chen Baoan
Department of Hematology and Oncology (Key Department of Jiangsu Medicine), Zhongda Hospital, Medical School, Southeast University, Nanjing, Jiangsu Province, People's Republic of China.
Onco Targets Ther. 2015 Apr 24;8:955-7. doi: 10.2147/OTT.S83961. eCollection 2015.
Dasatinib, a second-generation tyrosine kinase inhibitor, is used for treating patients with Philadelphia chromosome (Ph) positive leukemia, especially for those who are resistant or intolerant to imatinib. The common adverse effects associated to its use include myelosuppression, nausea, diarrhea, and peripheral edema. This study reports a very rare case of a 60-year-old male who suffered from severe thrombocytopenia after dasatinib administration. The platelet count did not increase even after dasatinib had been discontinued for more than 6 months. Various means had been tried, but the count of platelet did not increase, and the result was not optimistic. This is the first report of so severe thrombocytopenia after dasatinib treatment, and the pathophysiology underlying this reaction remains unknown. We hope that this case will help remind clinicians to pay more attention to the side effect of thrombocytopenia caused by dasatinib in the future.
达沙替尼是一种第二代酪氨酸激酶抑制剂，用于治疗费城染色体（Ph）阳性白血病患者，尤其是那些对伊马替尼耐药或不耐受的患者。使用该药常见的不良反应包括骨髓抑制、恶心、腹泻和外周水肿。本研究报告了一例非常罕见的病例，一名60岁男性在服用达沙替尼后出现严重血小板减少。即使达沙替尼停药超过6个月，血小板计数仍未增加。尝试了各种方法，但血小板计数仍未增加，结果不容乐观。这是达沙替尼治疗后出现如此严重血小板减少的首例报告，这种反应的病理生理学尚不清楚。我们希望该病例能提醒临床医生今后更加关注达沙替尼引起的血小板减少副作用。
